Nama Insights

Braveheart Bio, Inc. Common Stock (BRVE)

Healthcare · Biotechnology · NASDAQ

Braveheart Bio, Inc. Common Stock (BRVE) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.58B. Nama's AI scorecard rates it Hold, 4.3 out of 10.
AI scorecard
Hold · 4.3/10
The sections balance. As of Nov 20, 2026.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-36.3%
How far the last close sits under the highest price of the past five years.
Market cap$1.58B
Trailing P/E—
Price / book3.5
Price / sales—
FCF yield—
Dividend yield—
Gross margin0.0%
Operating margin0.0%
Net margin0.0%
Revenue growth (YoY)—
Revenue growth (3-yr annual)—
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta—
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

BRVE earnings

Next report: Mar 18, 2027 (Q4 2026, EPS estimate -$0.27). Beat the EPS estimate in 1 of 2 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 10, 2026 -$0.51 -$0.60 +15.0% $0
Q2 2026 Sep 8, 2026 -$2.51 $2.69 -193.3% $0

BRVE analyst price target

Median target $46.50 from 4 analysts, ranging $40.00 – $49.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live BRVE data on Nama Insights →

BRVE FAQ

Is BRVE a buy?
Nama's AI scorecard currently rates Braveheart Bio, Inc. Common Stock Hold (4.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does BRVE report earnings?
Braveheart Bio, Inc. Common Stock's next scheduled report is on Mar 18, 2027. Analysts expect EPS of -$0.27.
What is the BRVE price target?
The median analyst price target from 4 analysts is $46.50, with a range of $40.00 – $49.00.
Is BRVE Shariah compliant?
Nama's AAOIFI-style screen reads Braveheart Bio, Inc. Common Stock as Can't Tell. A figure the screen needs is missing, so it can't tell.